Axonics Secures Regulatory Approval for Advanced Fourth-Generation Rechargeable SNM System in Australia’
Irvine, Calif. October 9, 2023’ Axonics, Inc. (Nasdaq: AXNX), a global leader in the development of innovative therapies for the treatment of bladder and bowel dysfunction, has announced that it has obtained regulatory approval from the Therapeutic Goods Administration (TGA) to market its latest advancement, the Axonics R20 rechargeable sacral neuromodulation (SNM) system, in Australia. This approval marks a pivotal milestone in providing Australian patients with groundbreaking treatment options for overactive bladder and fecal incontinence.
Enhance Quality of Life
The fourth-generation Axonics R20 system is engineered to revolutionize patient management and treatment outcomes for those suffering from pelvic floor disorders. Notably, the R20 neurostimulator is designed with an impressive functional life expectancy of at least 20 years, ensuring long-term reliability and performance for patients. This level of durability represents a significant step forward in SNM technology, addressing a common concern regarding the longevity of implanted devices.
Reduced Recharge Frequency
One of the standout features of the Axonics R20 system is its remarkably reduced need for recharging. Patients with the R20 neurostimulator will only need to recharge their device once every six months, a substantial improvement over previous generations that often required more frequent recharging sessions. This advancement in recharge efficiency is poised to enhance patient convenience and compliance, reducing the burden of frequent maintenance and further improving the quality of life for individuals undergoing SNM therapy.
Comprehensive Regulatory Approval
The TGA approval signifies that the Axonics R20 system has met stringent regulatory standards for safety, efficacy, and quality in Australia. Axonics’ commitment to rigorous clinical evaluations and adherence to regulatory protocols reinforces its position as a trusted leader in the medical device industry. The company’s innovative approach to SNM therapy consistently aims to address the evolving needs of patients and healthcare providers while setting new standards for treatment efficacy and patient care.
Addressing Overactive Bladder and Fecal Incontinence
Overactive bladder (OAB) and fecal incontinence are prevalent and often debilitating conditions that significantly impact the lives of millions of individuals worldwide. The Axonics R20 system provides a compelling therapeutic option by delivering gentle electrical stimulation to the sacral nerves, which play a crucial role in regulating bladder and bowel function. This neurostimulation therapy effectively targets the underlying mechanisms of pelvic floor disorders, offering relief to patients who have not responded adequately to conventional treatments.
Strategic Market Expansion
Axonics’ entry into the Australian market with the R20 system aligns with the company’s broader strategy of expanding its global footprint and making its advanced SNM solutions accessible to a wider patient population. The approval from the TGA enables Axonics to collaborate with healthcare providers across Australia, empowering them with cutting-edge tools to address the unmet needs of patients suffering from bladder and bowel dysfunction.
We are thrilled to receive regulatory clearance from the TGA for our fourth-generation Axonics R20 system, said Raymond W. Cohen, Chief Executive Officer of Axonics. This approval underscores our commitment to advancing SNM technology and improving the lives of individuals with OAB and fecal incontinence. We look forward to working with Australian healthcare professionals to bring this innovative therapy to patients in need.
Looking Ahead
The Axonics R20 rechargeable sacral neuromodulation system represents a monumental advancement in the field of neuromodulation therapy. With its extended functional life, reduced maintenance requirements, and proven efficacy, the R20 system is poised to set new benchmarks for treating overactive bladder and fecal incontinence. As Axonics continues to innovate and push the boundaries of medical technology, patients in Australia and beyond can anticipate improved therapeutic outcomes and enhanced quality of life.
Comments